Amyloidosis Research Consortium is hosting a critical meeting with the FDA in Bethesda on November 16th, 2015. This is an unprecedented opportunity: patients can inform the FDA about their experience and unmet needs. At the FDA's request, amyloidosis experts will present the challenges of clinical trials and a pathway for promising and effective treatments to be effectively and swiftly evaluated.
This is a call for action. Admission to this meeting is free. To find out more and reserve your place, contact email@example.com.